Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes

Nature Communications

Volumn 5, Issue , 2014, Pages

  Dhanasekaran, Saravana M ^a   Balbin, O Alejandro ^a   Chen, Guoan ^a   Nadal, Ernest ^a   Kalyana Sundaram, Shanker ^a   Pan, Jincheng ^a   Veeneman, Brendan ^a   Cao, Xuhong ^a   Malik, Rohit ^a   Vats, Pankaj ^a   Wang, Rui ^a   Huang, Stephanie ^a   Zhong, Jinjie ^b   Jing, Xiaojun ^a   Iyer, Matthew ^a   Wu, Yi Mi ^a   Harms, Paul W ^a   Lin, Jules ^a   Reddy, Rishindra ^a   Brennan, Christine ^a   Palanisamy, Nallasivam ^a   Chang, Andrew C ^a   Truini, Anna ^c   Truini, Mauro ^c   Robinson, Dan R ^a   Beer, David G ^a   Chinnaiyan, Arul M ^a   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b XINJIANG MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MESSENGER RNA; TRANSCRIPTOME; B LYMPHOCYTE ANTIGEN; HIPPO PROTEIN, HUMAN; HLA ANTIGEN CLASS 2; INVARIANT CHAIN; NEU DIFFERENTIATION FACTOR; NEUROFIBROMIN; NRG1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

CANCER; GENE EXPRESSION; GENETIC ANALYSIS; GERM CELL; META-ANALYSIS; MUTATION;

ADULT; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DCHS2 GENE; EXON SKIPPING; FAT1 GENE; FOLLOW UP; GENE; GENE FUSION; GENE MUTATION; HUMAN; HUMAN CELL; LATS1 GENE; LUNG CANCER; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NEUREGULIN 1 GENE; NEUROFIBROMATOSIS 1 GENE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RNA SEQUENCE; SMARCA4 GENE; SOMATIC MUTATION; TAOK1 GENE; TAOK3 GENE; TP53 GENE; TUMOR SUPPRESSOR GENE; EXON; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; META ANALYSIS; METABOLISM; MORTALITY; MUTATION; SIGNAL TRANSDUCTION;

ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; EXONS; GENE EXPRESSION PROFILING; GENE FUSION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUNG NEOPLASMS; MUTATION; NEUREGULIN-1; NEUROFIBROMIN 1; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84923256369     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6893     Document Type: Article

References (57)

1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
3. Nakamura, H. & Saji, H. A worldwide trend of increasing primary adenocarcinoma of the lung. Surg. Today 44, 1004-1012 (2013).
4. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
5. Weir, B. A. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898 (2007).
6. Pao, W. & Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175-180 (2011).
7. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
8. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
9. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
10. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
11. Inamura, K. et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod. Pathol. 22, 508-515 (2009).
12. Takeuchi, K. et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 15, 3143-3149 (2009).
13. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
14. Ju, Y. S. et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 22, 436-445 (2012).
15. Takeuchi, K. et al. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18, 378-381 (2012).
16. Drilon, A. et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 3, 630-635 (2013).
17. Wang, X. S. et al. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat. Biotechnol. 27, 1005-1011 (2009).
18. Wu, Y. M. et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636-647 (2013).
19. Seo, J. S. et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22, 2109-2119 (2012).
20. Fernandez-Cuesta, L. et al. CD74-NRG1 Fusions in Lung Adenocarcinoma. Cancer Discov. 4, 415-422 (2014).
21. Gow, C. H., Wu, S. G., Chang, Y. L. & Shih, J. Y. Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case. Med. Oncol. 31, 34 (2014).
22. Nakaoku, T. et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin. Cancer Res. 20, 3087-3093 (2014).
23. Kong-Beltran, M. et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 66, 283-289 (2006).
24. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci. Transl. Med. 5, 209ra153 (2013).
25. Ho, A. S. et al. The mutational landscape of adenoid cystic carcinoma. Nat. Genet. 45, 791-798 (2013).
26. Wetterskog, D. et al. Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology 62, 543-550 (2013).
27. Wetterskog, D. et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J. Pathol. 226, 84-96 (2012).
28. Zhao, B., Li, L., Lei, Q. & Guan, K. L. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 24, 862-874 (2010).
29. Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246-257 (2013).
30. Bollag, G. et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 12, 144-148 (1996).
31. Sandsmark, D. K. et al. Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res. 67, 4790-4799 (2007).
32. Onozato, R. et al. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J. Thorac. Oncol. 4, 5-11 (2009).
33. Falls, D. L. Neuregulins: functions, forms, and signaling strategies. Exp. Cell Res. 284, 14-30 (2003).
34. Holmes, W. E. et al. Identification of heregulin, a specific activator of p185erbB2. Science 256, 1205-1210 (1992).
35. Wen, D. et al. Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol. Cell Biol. 14, 1909-1919 (1994).
36. rd K. L. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1. Mol. Cell Biol. 27, 2180-2188 (2007).
37. Sholl, L. M. et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am. J. Clin. Pathol. 133, 922-934 (2010).
38. Lipson, D. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382-384 (2012).
39. Koivunen, J. P. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275-4283 (2008).
40. Shaw, A. T. et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012 (2011).
41. Tanas, M. R. et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci. Transl. Med. 3, 98ra82 (2011).
42. Errani, C. et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 50, 644-653 (2011).
43. Mohseni, M. et al. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat. Cell Biol. 16, 108-117 (2014).
44. Montero, J. C. et al. Neuregulins and cancer. Clin. Cancer Res. 14, 3237-3241 (2008).
45. Sugano, M. et al. HNF4alpha as a marker for invasive mucinous adenocarcinoma of the lung. Am. J. Surg. Pathol. 37, 211-218 (2013).
46. Adelaide, J. et al. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene. Genes Chromosomes Cancer 37, 333-345 (2003).
47. Prentice, L. M. et al. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene 24, 7281-7289 (2005).
48. Gollamudi, M., Nethery, D., Liu, J. & Kern, J. A. Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines. Lung Cancer 43, 135-143 (2004).
49. Hegde, G. V. et al. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci. Transl. Med. 5, 171ra118 (2013).
50. Levin, J. Z. et al. Comprehensive comparative analysis of strand-specific RNA sequencing methods. Nat. Methods 7, 709-715 (2010).
51. Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
52. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012).
53. Tibshirani, R. & Hastie, T. Outlier sums for differential gene expression analysis. Biostatistics 8, 2-8 (2007).
54. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
55. Carrara, M. et al. State of art fusion-finder algorithms are suitable to detect transcription-induced chimeras in normal tissues? BMC Bioinformatics 14(Suppl 7): S2 (2013).
56. Carrara, M. et al. State-of-the-art fusion-finder algorithms sensitivity and specificity. BioMed. Res. Int. 2013, 340620 (2013).
57. Ozsolak, F. & Milos, P. M. RNA sequencing: advances, challenges and opportunities. Nat. Rev. Genet. 12, 87-98 (2011).